drugset / Trial / NCT05416125

Vyvanse in Children Aged 6 to 12 Years

NCT05416125

Phase 0 Completed 44 enrolled University of Minnesota
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will randomize children who have difficulty maintaining a healthy weight to one of two treatment groups: lifestyle therapy plus lisdexamfetamine or lifestyle therapy plus placebo.

Timeline

Start
2023-12-20
Primary completion
2026-06-23
Completion
2026-06-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lisdexamfetamine Dimesylate Small molecule

Indications